GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting
in gross proceeds of NOK 33 million.
Reference is made to the stock exchange announcement published on 27 January
2026 by EXACT Therapeutics, announcing that:
o The Trial Monitoring Committee has issued a positive conclusion for the
pre-planned safety read-out and the phase 2 trial proceeds as planned.
o This triggers the option to exercise Warrants.
o Early, encouraging tumour shrinkage, and significant decrease in tumour
biomarker CA 19-9 (>85% decrease, unaudited data).
Oslo, Norway, 5 February 2026. Reference is made to the stock exchange
announcement by EXACT Therapeutics AS (the "Company", Euronext Growth ticker:
EXTX), a clinical-stage precision medicine company, on 27 January 2026,
referring to the Company's private placement completed on 3 December 2024 (the
"Private Placement"), in which the participants received a right to subscribe
for additional shares (the "Warrants") following the announcement of the initial
safety read-out from the phase 2 ENACT trial in locally advanced pancreatic
cancer.
As announced on 27 January 2026, the positive safety read-out triggered the
potential exercise of warrants issued at the financing in December of 2024. The
Company is pleased to announce that GE Medical Holding AB ("GEMH"), a subsidiary
of GE HealthCare Technologies Inc., has today, 5 February 2026, confirmed that
it will exercise all of its 26,973,169 Warrants. The exercise of GEMH's Warrants
will result in gross proceeds of NOK 33 million to the Company The remaining
Warrants holders in the program may exercise their Warrants within 15 business
days from today's date, i.e. within 26 February 2026. Updates on the Warrants
exercise will follow in due course.
"We are excited about our collaboration with EXACT Therapeutics and their
important clinical milestone in the ENACT phase 2 pancreatic cancer trial," said
Karley Yoder, CEO, Comprehensive Care Ultrasound, GE HealthCare. "With the
exercise of the warrants, we look forward to further unlocking the potential of
EXACT's ultrasound-activated therapy and its potential benefit for pancreatic
cancer patients."
Information in this announcement is considered inside information pursuant to EU
Market Abuse Regulation (MAR) and subject to the disclosure requirements
pursuant to MAR Article 17 and Section 5-12 of the Norwegian Securities Trading
Act. This stock exchange announcement was published by John M. Edminson, CFO, on
08:30 (CET) 5 February 2026.
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are traded on Euronext Growth Oslo (EXTX). Further
information may be found here: www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com